Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2022-01-18 Capital/Financing Update
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
News release - French.pdf
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 18 January 2022 from AIC Mines. It details the acquisition of new exploration projects, specifically the application for two large exploration licenses in western New South Wales. The content focuses on the company's strategic exploration activities, geological overview, and proposed exploration plans. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about a new project acquisition rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the project and company strategy. The document fits best into the category of Capital/Financing Update (CAP) as it relates to company growth through acquisition of exploration assets and expansion of capital projects.
2022-01-18 English
News release - English.pdf
Investor Presentation Classification · 85% confidence The document is a press release announcing Resverlogix's participation in upcoming scientific conferences and presentations by its research scientists. It focuses on research topics, clinical trials, and company background, without containing any financial data, regulatory filings, or detailed financial reports. There is no indication of an earnings release, annual or interim report, or any other formal financial filing. The content is informational about scientific presentations and company research activities, which aligns with an Investor Presentation (IP) as it provides detailed information for investors about the company's scientific progress and strategy. The document length (6213 characters) supports it being a full announcement rather than a brief notice. Therefore, the best fitting category is Investor Presentation (IP).
2021-10-29 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the successful completion and positive results of a clinical pilot study (APPROACH-p trial) for the drug apabetalone in treating pulmonary arterial hypertension. It details study rationale, design, key findings, and next steps including plans for a larger trial. There are no financial statements, regulatory filings, or detailed financial data. The content is focused on clinical trial results and company product development updates, typical of a Capital/Financing Update or clinical progress announcement. It is not an earnings release, annual report, or regulatory filing. Given the nature of the announcement about a clinical trial milestone and future plans, the best fitting category is Capital/Financing Update (CAP), as it relates to company progress that could impact financing or investor interest. Confidence is high due to clear clinical trial announcement and no financial report content.
2021-09-08 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO of Resverlogix Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3363 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2021-08-17 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the President and CEO of Resverlogix Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3375 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2021-08-17 English
Interim MD&A - English.pdf
Regulatory Filings
2021-08-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.